Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia
NCT00862992
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Schizophrenia
Interventions
DRUG:
Cariprazine 3 mg
DRUG:
Cariprazine 6 mg
DRUG:
Cariprazine 12.5 mg
Sponsor
Tanabe Pharma Corporation